10-K: Annovis Bio's Buntanetap Advances in AD, PD Trials; Faces Going Concern

Annovis Bio reports progress in its pivotal Phase 3 Alzheimer's and Open-Label Extension Parkinson's trials for buntanetap, while acknowledging substantial doubt about its ability to continue as a going concern without additional financing.

Summary

• Annovis Bio is a late-stage clinical drug platform company focused on neurodegeneration, specifically Alzheimer's disease (AD) and Parkinson's disease (PD).
• Its lead product candidate, buntanetap, is an orally administered small molecule designed to inhibit the synthesis of neurotoxic proteins (APP/A, tau/phospho-tau, α-Synuclein, TDP43) implicated in neurodegeneration.
• Clinical studies in AD and PD patients, and preclinical studies, have shown buntanetap lowered neurotoxic protein levels, improved axonal transport, reduced inflammation, decreased nerve cell death, and improved affected function.
• A pivotal Phase 3 AD Trial (NCT06709014) in 760 early AD patients was initiated in February 2025, with a 6-month symptomatic efficacy period and an additional 12-month disease-modifying efficacy period.
• An Open-Label Extension (OLE) study (NCT07284784) for PD patients began in January 2026, aiming to enroll 500 patients for 36 months to evaluate long-term safety and efficacy.
• The company received FDA approval to proceed with a planned Phase 3 study in Parkinson's disease dementia (PDD), contingent on additional funding.
• Topline efficacy data from the Phase 3 PD Trial (completed December 2023, released July 2024) showed buntanetap improved UPDRS Part II, III, II+III, and total scores in subgroups, stopped cognition loss in the entire ITT population, and improved cognition in cognitively impaired PD patients.
• Topline efficacy data from the Phase 2/3 AD Trial (completed February 2024, announced April 2024) showed buntanetap improved ADAS-Cog11 in early AD patients in a dose-dependent and statistically significant manner.
• Annovis and the FDA have aligned on a development path for buntanetap towards filing New Drug Applications (NDAs) for both short-term and long-term efficacy in AD.
• The company reported a net loss of $28.9 million for the year ended December 31, 2025, compared to $24.6 million for 2024.
• Operating loss was $29.7 million for 2025, up from $26.7 million in 2024.
• Cash and cash equivalents were $19.5 million as of December 31, 2025, with an accumulated deficit of $163.7 million.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for the next twelve months without additional financing.
• The company raised $5.5 million net proceeds from a registered direct offering in October 2025 (3.15M shares + 850k pre-funded warrants at $1.50/$1.4999).
• Another registered direct offering in October 2025 raised $3.1 million net proceeds (1.67M shares at $2.05), including purchases by two board members.
• A February 2025 underwritten public offering of 5.3 million units (common stock + warrants) generated $19.3 million net proceeds.
• The company sold 2.1 million shares through an ATM facility for $6.8 million gross proceeds in 2025.
• Subsequent to December 31, 2025, through March 11, 2026, the company sold an additional 1.2 million shares via ATM for $3.3 million net proceeds.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While clinical progress for buntanetap in AD and PD is positive and FDA interactions are favorable, the significant and increasing net losses, coupled with the explicit 'going concern' warning and NYSE listing non-compliance, present substantial financial risks that overshadow the clinical advancements.

Positives

• Initiation of a pivotal Phase 3 AD Trial in 760 early AD patients, with a design to assess both symptomatic and disease-modifying efficacy.
• FDA clearance for the pivotal Phase 3 AD Trial and alignment on a development path for NDA filings for short-term and long-term efficacy.
• Initiation of an Open-Label Extension (OLE) study in PD patients to evaluate long-term safety and efficacy and meet FDA patient exposure requirements.
• FDA approval to proceed with a planned Phase 3 study in Parkinson's disease dementia (PDD), following strong cognition data in amyloid-positive PD patients.
• Positive topline efficacy data from the Phase 3 PD Trial, showing improvement in UPDRS scores in subgroups and statistically significant cognition improvement in cognitively impaired PD patients.
• Positive topline efficacy data from the Phase 2/3 AD Trial, demonstrating dose-dependent and statistically significant improvement in ADAS-Cog11 in early AD patients.
• FDA raised no safety concerns regarding buntanetap's impact on liver enzymes, drug interactions, dose selection, PK, and population PK during the end-of-phase 2 meeting for AD.
• FDA confirmed that future development can proceed using the new crystal form of buntanetap.
• Buntanetap's mechanism of action is designed to inhibit multiple neurotoxic proteins (APP, tau, SYN, TDP43), which is a novel approach in AD and PD drug development.
• The company has a robust patent portfolio with 40 issued patents and 48 pending applications, with expiration dates extending to 2045, including coverage for a new crystal form (Posiphen Form B/ANVS402) with advantageous properties.
• Successful capital raises in 2025, including $19.3 million from an underwritten offering, $5.5 million and $3.1 million from registered direct offerings, and $6.8 million gross from an ATM facility.

Negatives

• Recurring operating losses and accumulated deficit raise substantial doubt about the company's ability to continue as a going concern.
• Net loss increased to $28.9 million in 2025 from $24.6 million in 2024.
• Operating loss increased to $29.7 million in 2025 from $26.7 million in 2024.
• Cash and cash equivalents of $19.5 million as of December 31, 2025, are not sufficient to fund operations for at least the next twelve months.
• The company will require substantial additional capital to fund ongoing clinical trials and future operations.
• The auditors' opinion on the financial statements for 2025 includes an explanatory paragraph relating to the going concern uncertainty.
• The company has a limited operating history and no history of commercializing pharmaceutical products.
• The market price of common stock has been volatile and fluctuated substantially.
• The company received a notice from the NYSE on March 26, 2025, for non-compliance with continued listing standards (average market capitalization < $50 million and stockholders' equity < $50 million).

Risks

• Recurring operating losses, negative cash flows, and accumulated deficit raise substantial doubt about the ability to continue as a going concern.
• Need for substantial additional capital to fund operations; failure to obtain funding could lead to delays, reductions, or termination of development.
• Limited operating history and no history of commercializing pharmaceutical products.
• Heavy dependence on the success of buntanetap; failure to obtain regulatory approval or commercialize it would materially harm the business.
• Concentration of R&D efforts on AD and PD, diseases with historically limited drug development success, and buntanetap's novel approach makes development time and cost difficult to predict.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes, including potential delays in patient enrollment and retention.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable; approval may be delayed or denied.
• Results of preclinical studies, early clinical trials, or interim data may not be indicative of results obtained in later trials or final data.
• Product candidates may cause serious adverse events or undesirable side effects, potentially delaying or preventing marketing approval or limiting sales.
• Market opportunities for buntanetap may be smaller than anticipated.
• Extensive and ongoing regulatory requirements and obligations even if approval is obtained, with potential for future development and regulatory difficulties.
• Significant competition from other biotechnology and pharmaceutical companies.
• Successful commercialization depends on market acceptance, adequate coverage, reimbursement levels, and pricing policies.
• Risks associated with operating internationally.
• Reliance on third parties for manufacturing and clinical trials; failure of these third parties could harm the business.
• Changes in manufacturing methods or formulation may result in additional costs or delays.
• Enacted and future healthcare legislation may increase difficulty and cost of obtaining approval and commercializing products.
• Inability to obtain, maintain, and enforce patent or other intellectual property protection, or if the scope is not broad enough, competitors could commercialize similar products.
• Claims challenging inventorship of patents or alleging infringement of third-party rights, leading to costly and time-consuming lawsuits.
• Cash and cash equivalents held in deposit accounts at two financial institutions exceed FDIC limits, posing a risk of loss or delay in access if institutions fail.
• Volatile market price of common stock.
• Past and potential future securities class action litigation.
• NYSE continued listing non-compliance notice received March 26, 2025, with an 18-month period to regain compliance.
• Dependence on key personnel and ability to attract, retain, and motivate qualified personnel.
• Difficulties in managing anticipated growth.
• Risks associated with potential future acquisitions.
• Risks related to entering into collaborations, license agreements, and similar arrangements.
• Failures involving information technology systems or cybersecurity breaches.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws.
• Subject to environmental, health, and safety laws and regulations.
• Recent U.S. tax legislation may materially adversely affect financial condition.

Future Outlook

The company expects to incur significant additional operating losses for the next several years as it advances buntanetap and other product candidates through clinical development, seeks regulatory approval, and potentially commercializes them. Research and development expenses are expected to remain elevated in 2026 and beyond due to ongoing Phase 3 AD trials, the OLE PD study, and the planned Phase 3 PDD trial, leading up to potential NDA filings. The company plans to explore various dilutive and non-dilutive opportunities, including equity and debt financings, strategic partnerships, and business development, to secure substantial additional financing required to fund operations beyond Q3 2026 and complete development and commercialization of its product candidates.

Management Comments

• We believe that we are the only company developing a drug for AD and PD that inhibits more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity.
• Based on preclinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD.
• Our ultimate goal is to develop a disease modifying drug (DMD) for patients with neurodegeneration by leveraging our clinical and preclinical data, which shows inhibition of the most relevant neurotoxic proteins.
• We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.
• We believe that our current cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2026.
• Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for the next twelve months from the date of the financial statements included in this Annual Report on Form 10-K.

Industry Context

StockSavvy.ai notes that Annovis Bio's focus on a multi-target approach (inhibiting APP, tau, SYN, TDP43) for neurodegenerative diseases like AD and PD is innovative, contrasting with the historical industry trend of targeting single neurotoxic proteins, which has seen limited success. The high failure rate in AD drug development (8% success rate for Phase 2/3 trials from 2004-2025) underscores the significant challenge Annovis faces. The company's progress with buntanetap in improving cognition and motor function in early AD and PD patients, if sustained in larger trials, could position it uniquely in a market largely dominated by symptomatic treatments and with few disease-modifying therapies. The increasing prevalence of AD and PD with an aging global population highlights the substantial unmet medical need that Annovis aims to address.

Comparison to Industry Standards

• Annovis Bio's buntanetap, by targeting multiple neurotoxic proteins (APP, tau, SYN, TDP43), contrasts with many industry efforts that have focused on single targets, such as amyloid-beta (Aβ) or tau. For example, many Aβ-targeting approaches have failed or shown limited efficacy in AD.
• The company's claim of buntanetap being "the only drug to improve cognition in AD and motor function in PD" positions it against existing symptomatic treatments like Levodopa for PD and cholinesterase inhibitors/memantine for AD, which do not address disease modification.
• The success rate for AD drug candidates in Phase 2 and 3 clinical trials (8% from 2004 to 2025) is significantly lower than for other drug candidates (50% to 80%), indicating the high bar for Annovis's development.
• The FDA's stance that one single Phase 3 trial is adequate for approval only if it demonstrates "robust and unquestionable efficacy" sets a high standard for Annovis's pivotal AD trial, which is designed with both 6-month symptomatic and 18-month disease-modifying endpoints.
• The company's OLE study for PD patients, aiming for 36 months of treatment, is crucial for meeting FDA patient exposure requirements, a common hurdle in long-term drug development.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceedings that could have a material adverse effect on its business, operating results, or financial condition.
• Two securities class action complaints were filed against the company and executive officers during 2021 following disclosure of interim AD/PD trial results, but both were voluntarily dismissed without prejudice by the plaintiffs.

Related Party Transactions

• Two members of the Board of Directors agreed to purchase an aggregate of 1,073,171 shares of Common Stock in a registered direct offering on October 26, 2025, at $2.05 per share.

Stakeholder Impact

• Shareholders: Potential for significant dilution from ongoing and future capital raises. Risk of substantial losses due to stock price volatility and the "going concern" uncertainty. Potential for increased value if buntanetap achieves regulatory approval and commercial success.
• Employees: Continued employment and potential for equity incentives are tied to the company's ability to secure funding and achieve milestones. Risk of job insecurity if operations are curtailed due to lack of capital.
• Customers (future): If approved, patients with AD and PD could benefit from a novel disease-modifying treatment.
• Creditors: Increased risk due to the "going concern" uncertainty and reliance on future financing.
• Suppliers/CROs: Continued engagement and payments are dependent on the company's financial health and ability to secure funding for ongoing and planned trials.

Next Steps

• Complete the 6-month symptomatic component of the Phase 3 AD trial (expected readout in H2 2026).
• Complete the 18-month disease-modifying component of the Phase 3 AD trial (expected readout in H2 2027).
• Continue the Open-Label Extension (OLE) study in PD patients for 36 months or until buntanetap is on the market.
• Refine the proposed protocol for the Parkinson's disease dementia (PDD) program and initiate the study contingent on additional funding.
• Seek additional grant funding to further the development of ANVS405 for acute indications of brain and nerve trauma.
• Conduct a follow-on study to evaluate the effect of ANVS405 administered to TBI rats at various intervals post-injury.
• Conduct toxicology and PK studies in animals for ANVS405.
• File Investigational New Drug (IND) application for ANVS405.
• Conduct safety and PK studies in humans for ANVS405, followed by Phase 2 and Phase 3 efficacy studies.
• Potentially file New Drug Applications (NDAs) for buntanetap in AD (short-term and long-term efficacy).
• Potentially petition the FDA to classify buntanetap as a breakthrough therapy.
• Seek New Chemical Entity status for Posiphen Form B (ANVS402) before the FDA and additional regulatory exclusivity.
• Further file patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications for Posiphen Form B and new manufacturing methods.
• Establish sales and marketing agreements with pharmaceutical companies if buntanetap is approved.
• Continue to implement and improve managerial, operational, and financial systems to manage anticipated growth.
• Recruit and train additional qualified personnel.
• Formalize cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.

Key Dates

Recommendation

While Annovis Bio has shown promising clinical data for buntanetap in AD and PD and has a novel mechanism of action, the significant financial distress, including recurring and increasing net losses, an accumulated deficit of over $163 million, and an explicit "going concern" warning from auditors, presents an extremely high risk profile. The current cash runway only extends into Q3 2026, necessitating substantial additional capital raises in a volatile market. Furthermore, the NYSE non-compliance notice adds to the uncertainty. Despite clinical progress, the fundamental financial viability is severely questioned, making the stock a "sell" for seasoned investors until a clear path to sustainable funding and profitability is established.

Keywords

Neurodegeneration, Alzheimer's Disease, Parkinson's Disease, Buntanetap, Clinical Trials, Phase 3, Drug Development, Biotechnology, SEC Filing, 10-K, Going Concern, Capital Raise, Intellectual Property, FDA Approval, ADAS-Cog, UPDRS, Neurotoxic Proteins, ANVS405, ANVS301, Parkinson's Disease Dementia